Andrew Clark, PhD, D(ABMM) is the Associate Director of Microbiology at Clements University Hospital at the University of Texas Southwestern Medical Center.  He is also an assistant professor in the Department of Pathology. 

Dr. Clark received his undergraduate, masters, and doctoral degrees in Microbiology from the University of Arizona, Tucson AZ.  He then completed a CPEP-accredited postdoctoral fellowship training program in Clinical and Public Health Microbiology at the National Institutes of Health in Bethesda, MD.  Dr. Clark is board certified in Medical and Public Health Microbiology by the American Board of Medical Microbiology.  His research and academic interests are focused on the molecular mechanisms of antimicrobial resistance and antimicrobial susceptibility testing in the clinical microbiology laboratory.  He is also interested in the pathophysiology and antimicrobial resistance of anaerobic bacteria, and the evaluation and implementation of novel diagnostic technologies.


Undergraduate School
University of Arizona (2006)
Graduate School
University of Arizona (2009)
Graduate School
University of Arizona (2017)
National Institutes of Health (NIH) (2019)

Research Interest

  • Antimicrobial resistance mechanisms and pathophysiology of anaerobic bacteria
  • Antimicrobial susceptibility testing
  • Evaluation of diagnostic technologies and diagnostic test utilization in the clinical microbiology laboratory


Featured Publications LegendFeatured Publications

In vitro activity of cefiderocol against Pseudomonas aeruginosa isolated from cystic fibrosis patients.
Monogue ML, Desai D, Pybus CA, Sanders JM, Clark AE, Greenberg DE, Microbiol Spectr 2023 Nov e0304723
Limited Clinical Utility of Routine Mycobacterial Cultures for the Management of Diabetic Foot Infections.
Castellino LM, McCormick-Baw C, Coye T, Crisologo PA, Hanna JJ, Lee F, Clark A, Fanning M, Killeen AL, Open Forum Infect Dis 2023 Nov 10 11 ofad558
A conceptual framework for nomenclatural stability and validity of medically important fungi: a proposed global consensus guideline for fungal name changes supported by ABP, ASM, CLSI, ECMM, ESCMID-EFISG, EUCAST-AFST, FDLC, IDSA, ISHAM, MMSA, and MSGERC.
de Hoog S, Walsh TJ, Ahmed SA, Alastruey-Izquierdo A, Alexander BD, Arendrup MC, Babady E, Bai F-Y, Balada-Llasat J-M, Borman A, Chowdhary A, Clark A, Colgrove RC, Cornely OA, Dingle TC, Dufresne PJ, Fuller J, Gangneux J-P, Gibas C, Glasgow H, Gräser Y, Guillot J, Groll AH, Haase G, Hanson K, Harrington A, Hawksworth DL, Hayden RT, Hoenigl M, Hubka V, Johnson K, Kus JV, Li R, Meis JF, Lackner M, Lanternier F, Leal SM, Lee F, Lockhart SR, Luethy P, Martin I, Kwon-Chung KJ, Meyer W, Nguyen MH, Ostrosky-Zeichner L, Palavecino E, Pancholi P, Pappas PG, Procop GW, Redhead SA, Rhoads DD, Riedel S, Stevens B, Sullivan KO, Vergidis P, Roilides E, Seyedmousavi A, Tao L, Vicente VA, Vitale RG, Wang Q-M, Wengenack NL, Westblade L, Wiederhold N, White L, Wojewoda CM, Zhang SX, J Clin Microbiol 2023 Oct e0087323
Ceftolozane/tazobactam heteroresistance in cystic fibrosis-related Pseudomonas aeruginosa infections.
Monogue ML, Sanders JM, Pybus CA, Kim J, Zhan X, Clark AE, Greenberg DE, JAC Antimicrob Resist 2023 Aug 5 4 dlad083
Antimicrobial Activity of Tebipenem and Comparators against Enterobacterales from diverse Outpatient Centers and Nursing Homes in the United States.
Asempa TE, Bobenchik AM, Bourassa L, Clark AE, Hatch MT, Huse HK, Martin IW, Mochon AB, Munson E, Sfeir MM, Srodon M, Wang Y, Nicolau DP, Int J Antimicrob Agents 2023 Jan 106733
The Brief Case: Encephalitis in a West Texas Woman.
McCormick-Baw C, Clark A, Knights S, Perl T, Cavuoti D, J Clin Microbiol 2022 Nov 60 11 e0227121


Featured Books Legend Featured Books

Professional Associations/Affiliations

  • American Society for Microbiology (2013)
  • Anaerobe Society of the Americas (2021)
  • Southwestern Association of Clinical Microbiology (2022)